Literature DB >> 22686329

Use of Sorafenib as an effective treatment in an AML patient carrying a new point mutation affecting the Juxtamembrane domain of FLT3.

Joaquín Martínez-López, Nerea Castro, Daniel Rueda, Alicia Canal, Carlos Grande, Rosa Ayala.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22686329     DOI： 10.1111/j.1365-2141.2012.09189.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  2 in total

1.  The Current State of FLT3 Inhibition in Acute Myeloid Leukemia - Pitfalls and Promises.

Authors:  Katherine A Minson; Deborah DeRyckere; Douglas K Graham
Journal:  J Cell Signal       Date:  2017-10-16

2.  Point Mutations in the FLT3-ITD Region Are Rare but Recurrent Alterations in Adult AML and Associated With Concomitant KMT2A-PTD.

Authors:  Sebastian Stasik; Michael Kramer; Sven Zukunft; Christoph Röllig; Claudia D Baldus; Uwe Platzbecker; Hubert Serve; Carsten Müller-Tidow; Kerstin Schäfer-Eckart; Martin Kaufmann; Stefan Krause; Tim Sauer; Mathias Hänel; Andreas Neubauer; Gerhard Ehninger; Martin Bornhäuser; Johannes Schetelig; Jan M Middeke; Christian Thiede
Journal:  Front Oncol       Date:  2022-03-21       Impact factor: 6.244
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.